Aleniglipron Phase 2 Body Composition Study
NCT07169942 on ClinicalTrials.gov · last registry update 2026-10-14
Finished 9 September 2026, after enrolling 71 people. Primary outcome, as filed: Percent change in total body fat mass by DXA. aleniglipron is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 3 times since then.
- Status
- COMPLETED
- Phase
- P2
- Drug
- aleniglipron
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Sponsor type
- Industry
- Enrollment
- 71
- Started
- 2025-08-15
- Primary completion
- 2026-09-09 actual
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-10-14 | Status changed | ACTIVE_NOT_RECRUITING → COMPLETED |
| 2026-10-14 | Reporting date moved | 2026-08 → 2026-09-09 1 months later |
| 2026-08-21 | First seen in registry | Registered as ACTIVE_NOT_RECRUITING, P2 |
Primary outcome
Percent change in total body fat mass by DXA
Conditions studied
Obesity, Overweight, or Chronic Weight Management
Every field above is taken directly from the registry record. See all detected changes across the class, or the aleniglipron page for this molecule’s full trial and approval history.